*Applications will be reviewed on a rolling-basis.

A Postdoctoral Fellow opportunity is available immediately with the Office of Commissioner (OC) Office of Women’s Health (OWH), U.S. Food and Drug Administration.  The opportunity will be with Dr. Wen Jin Wu and located at the Laboratory of Molecular Oncology (LMO), Division of Biotechnology Review and Research 2 (DBRR2), Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER) in Silver Spring, Maryland.

Under the guidance of the mentor, the participant will gain scientific background and research skills in the area of monoclonal and antibody-related therapeutic products. The participant will participate on a research project focusing on designing bispecific antibodies using genetic engineering approach, expressing bispecific antibodies from mammalian cells, and purifying bispecific antibodies using chromatography technologies. Under mentor supervision, the participant will learn to physio-chemically characterize bi-specific antibodies, biologically assess bi-specific antibodies using ovarian cancer cell model system, develop bioassays for bi-specific antibodies, analyze research data, and write scientific papers based on data obtained from the research project.

If you have questions about the nature of the research, please reach out to the mentor, Dr. Wen Jin Wu (wen.wu@fda.hhs.gov).

Anticipated Appointment Start Date: 2022

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA.  OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency.  This agreement covers such topics as the following:

Non-employee nature of the ORISE appointment
Prohibition on ORISE Fellows performing inherently governmental functions
Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship
The fact that research materials and laboratory notebooks are the property of the FDA
ORISE fellow’s obligation to protect and not to further disclose or use non-public information


The qualified candidate should have received a Ph.D. with an educational background in molecular and cell biology, pharmacology and drug discovery/development, or be currently pursuing the degree with completion by the end of 2022.  Degree must have been received within the past five years.

Lab skills in common molecular and cell biology techniques is preferred.